SECOND AMENDMENT TO LICENSE AGREEMENTLicense Agreement • May 1st, 2017 • Kitov Pharmaceuticals Holdings Ltd. • Pharmaceutical preparations
Contract Type FiledMay 1st, 2017 Company IndustryThis Second Amendment to License Agreement (“Second Amendment”) is effective as of 16 March 2017 (the “Effective Date”), by and between, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., of Hi Tech Park, Edmond J Safra Campus, Givat Ram, Jerusalem 91390 Israel, (“Yissum”) of the one part; and
SHAREHOLDER UNDERTAKING AND AGREEMENTShareholder Agreement • May 1st, 2017 • Kitov Pharmaceuticals Holdings Ltd. • Pharmaceutical preparations
Contract Type FiledMay 1st, 2017 Company IndustryThis SHAREHOLDER UNDERTAKING AND AGREEMENT (this “Undertaking”), dated as of January 13, 2017, is entered into by and among and Kitov Pharmaceuticals Holdings Ltd., an Israeli public company (“Company”) and Goldman Hirsh Partners Ltd. (the “Shareholder”).
THE SYMBOL “[****]” DENOTES PLACES WHERE PORTIONS OF THIS DOCUMENT HAVE BEEN OMIITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. SUCH MATERIAL HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION FIRST AMENDMENT TO LICENSE...License Agreement • May 1st, 2017 • Kitov Pharmaceuticals Holdings Ltd. • Pharmaceutical preparations • Texas
Contract Type FiledMay 1st, 2017 Company Industry JurisdictionThis First Amendment to License Agreement (“First Amendment”) is effective as of 8 April, 2014 (the “Effective Date”), by and between, YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD., of Hi Tech Park, Edmond J Safra Campus, Givat Ram, Jerusalem 91390 Israel, (“Yissum”) of the one part; and
AMENDMENT TO BINDING Term Sheet Dated February 9, 2017 [unofficial translation from hebrew to english]Binding Term Sheet Amendment • May 1st, 2017 • Kitov Pharmaceuticals Holdings Ltd. • Pharmaceutical preparations
Contract Type FiledMay 1st, 2017 Company IndustryThe agreements attached to this email are agreed upon by the Parties thereto as the final drafts thereof. Annex A to the document entitled “Binding Term Sheet” is amended as follows:
Flow of Funds AgreementFlow of Funds Agreement • May 1st, 2017 • Kitov Pharmaceuticals Holdings Ltd. • Pharmaceutical preparations
Contract Type FiledMay 1st, 2017 Company IndustryTHIS FLOW OF FUNDS AGREEMENT (this “Agreement”) is made and entered into as of April 9, 2017, by and among Goldman Hirsh Partners Ltd. (the “Seller”), and Kitov Pharmaceuticals Holdings Ltd. an Israeli publicly traded corporation or its Affiliated party (the "Buyer"), (each of the Seller, and the Buyer shall also be referred to as a “Party”, and collectively as the “Parties”).
Shareholders AgreementShareholders Agreement • May 1st, 2017 • Kitov Pharmaceuticals Holdings Ltd. • Pharmaceutical preparations
Contract Type FiledMay 1st, 2017 Company IndustryThis Shareholders Agreement (the “Agreement”) is entered into effective as of February 9, 2017, by and between Kitov Pharmaceuticals Holdings Ltd. an Israeli publicly traded corporation (“Parent”), on behalf of itself and, if Parent is not the buyer of the shares previously held by GHP (as defined hereunder), also on behalf of an as yet undetermined Affiliated party of Parent which shall, upon execution thereof by it, be deemed a Party to this Agreement Ab Initio (“Kitov”) and Taoz – Company for Management of Companies Ltd. (“Taoz”); each of Kitov and Taoz a “Party” and collectively the “Parties”.
LICENSE AGREEMENTLicense Agreement • May 1st, 2017 • Kitov Pharmaceuticals Holdings Ltd. • Pharmaceutical preparations
Contract Type FiledMay 1st, 2017 Company IndustryYISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD., of Hi Tech Park, Edmond J. Safra Campus, Givat Ram, Jerusalem 91390, Israel (“Yissum”) of the one part; and
STOCK PURCHASE AGREEMENTStock Purchase Agreement • May 1st, 2017 • Kitov Pharmaceuticals Holdings Ltd. • Pharmaceutical preparations
Contract Type FiledMay 1st, 2017 Company IndustryThis Stock Purchase Agreement (this “Agreement”) is entered into as of January 12, 2017, by and among Kitov Pharmaceuticals Holdings Ltd., an Israeli publicly traded corporation (“Parent”), on behalf of itself and, if Parent is not the buyer hereunder, also on behalf of an as yet undetermined Affiliated party of Parent which shall join this Agreement subsequent to the Closing (“Buyer”), and Goldman Hirsh Partners Ltd. (the “Seller”) which is a stockholder of Tyrovo Ltd., an Israeli private corporation (the “Company”). Parent, Buyer and Seller are sometimes referred to individually herein as a “Party” and collectively as the “Parties.”